Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TLR9 | Q9NR96 | 1/20 | 0.41 |
| ▸ | GAA | P10253 | 2/20 | 0.39 |
| ▸ | LMNA | P02545 | 1/20 | 0.39 |
| ▸ | MTNR1A | P48039 | 1/20 | 0.39 |
| ▸ | MTNR1B | P49286 | 1/20 | 0.39 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.38 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.38 |
| ▸ | PGR | P06401 | 7/20 | 0.38 |
| ▸ | HTT | P42858 | 2/20 | 0.36 |
| ▸ | NCOA1 | Q15788 | 1/20 | 0.36 |
| ▸ | NCOA3 | Q9Y6Q9 | 1/20 | 0.36 |
| ▸ | RAB9A | P51151 | 1/20 | 0.36 |
| ▸ | DRD2 | P14416 | 1/20 | 0.34 |
| ▸ | HTR2A | P28223 | 1/20 | 0.34 |
| ▸ | DRD3 | P35462 | 1/20 | 0.34 |
| ▸ | RBP4 | P02753 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL25259047 | 1.00 | TLR9 (0.41) | TLR9GAALMNAMTNR1AMTNR1B | |
| SCHEMBL8062901 | 0.85 | GAA (0.40) | TLR9GAALMNAMTNR1AMTNR1B | |
| SCHEMBL29410344 | 0.85 | GAA (0.40) | TLR9GAALMNAMTNR1AMTNR1B | |
| SCHEMBL8050676 | 0.80 | MTNR1A (0.42) | TLR9GAALMNAMTNR1AMTNR1B | |
| SCHEMBL29669030 | 0.77 | PGR (0.41) | TLR9PGR | |
| SCHEMBL20238144 | 0.77 | PGR (0.41) | TLR9PGR | |
| SCHEMBL29668841 | 0.77 | PGR (0.41) | TLR9PGR | |
| SCHEMBL20256905 | 0.77 | PGR (0.41) | TLR9PGR | |
| SCHEMBL20238703 | 0.77 | PGR (0.41) | TLR9PGR | |
| SCHEMBL25255980 | 0.76 | TEAD1 (0.42) | LMNAALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20160264512-A1 | C-HALOGEN BOND FORMATION | THE TRUSTEES OF PRINCETON UNIVERSITY (US) | 2016-09-15 | — | — | US | disclosed |
| WO-2015134467-A1 | METHODS AND COMPOSITIONS FOR DIRECT RADIOACTIVE LABELING OF BIO-ACTIVE MOLECULES AND BUILDING BLOCKS | THE TRUSTEES OF PRINCETON UNIVERSITY (US) | 2015-09-11 | — | — | WO | disclosed |
| WO-2015054476-A1 | C-HALOGEN BOND FORMATION | THE TRUSTEES OF PRINCETON UNIVERSITY (US) | 2015-04-16 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160264512-A1 | C-HALOGEN BOND FORMATION | FOS, BCL3, CBR3 | TLR9 4869/4885GAA 4774/4885LMNA 1885/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.